Bristol Myers Squibb Company (NYSE:BMY – Get Free Report)’s share price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $60.41 and traded as low as $59.48. Bristol Myers Squibb shares last traded at $59.4940, with a volume of 11,108,722 shares.
Top Bristol Myers Squibb Stories
These are some of the BMY stories that stood out recently:
- Neutral Sentiment: BMS reported initial Phase 3 ADEPT data for KarXT in psychosis associated with Alzheimer’s disease, an area with a significant treatment gap. The available report does not provide results on efficacy or safety, so the investment impact will depend on the full data. Article: Bristol Myers Squibb Is Pushing Deeper Into Neuroscience
- Neutral Sentiment: The company highlighted more than 90 updates across blood cancers and rare hematologic disorders at the ASH meeting. This underscores the breadth of its pipeline, but the reports provided do not specify data that would indicate a clear change in commercial prospects. Article: Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
- Negative Sentiment: Dividend-focused coverage points to a looming Eliquis patent-related revenue cliff, a risk to earnings and the sustainability of shareholder payouts as the drug faces future competition. Recent weakness in BMY shares despite pipeline news also signals investor caution. Article: 3 Big Pharma Dividend Stocks Built for Retirement Income
Analysts Set New Price Targets
A number of analysts have recently weighed in on BMY shares. Leerink Partners cut shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $73.00 to $59.00 in a report on Monday, October 5th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Bristol Myers Squibb in a research report on Monday. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Guggenheim reissued a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Bank of America reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Friday, October 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $65.46.
View Our Latest Research Report on Bristol Myers Squibb
Bristol Myers Squibb Price Performance
The firm has a market cap of $120.22 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. The stock has a 50 day moving average price of $61.45 and a two-hundred day moving average price of $60.44.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. Bristol Myers Squibb’s revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $1.63 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.
Bristol Myers Squibb Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.
Insiders Place Their Bets
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.05% of the company’s stock.
Institutional Investors Weigh In On Bristol Myers Squibb
Hedge funds have recently bought and sold shares of the stock. Pinion Investment Advisors LLC lifted its stake in shares of Bristol Myers Squibb by 3.8% in the 3rd quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 158 shares during the period. Altura Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 1.2% during the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock valued at $856,000 after buying an additional 161 shares during the period. Capital City Trust Co. FL grew its position in Bristol Myers Squibb by 0.7% during the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after buying an additional 167 shares during the period. Eagle Bay Advisors LLC grew its position in Bristol Myers Squibb by 2.6% during the third quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 168 shares during the period. Finally, Blue Bell Private Wealth Management LLC increased its holdings in Bristol Myers Squibb by 21.1% in the third quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
